REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) Director Kenneth T. Mills sold 20,602 shares of the firm's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director now directly owns 475,103 shares of the company's stock, valued at $3,758,064.73. This represents a 4.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
REGENXBIO Stock Up 1.8%
NASDAQ:RGNX opened at $8.33 on Thursday. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $16.85. The stock's fifty day simple moving average is $7.43 and its 200-day simple moving average is $7.99. The firm has a market capitalization of $417.47 million, a P/E ratio of -1.66 and a beta of 1.11.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.41 by ($0.29). The firm had revenue of $89.01 million for the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, equities research analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current year.
Institutional Investors Weigh In On REGENXBIO
Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its stake in REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock worth $31,975,000 after purchasing an additional 1,659,206 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after purchasing an additional 296,700 shares in the last quarter. Barclays PLC boosted its position in shares of REGENXBIO by 141.3% during the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock worth $1,217,000 after buying an additional 67,948 shares during the period. Wells Fargo & Company MN grew its holdings in shares of REGENXBIO by 34.0% during the fourth quarter. Wells Fargo & Company MN now owns 48,437 shares of the biotechnology company's stock worth $374,000 after buying an additional 12,285 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of REGENXBIO during the fourth quarter worth about $568,000. Institutional investors own 88.08% of the company's stock.
Wall Street Analyst Weigh In
RGNX has been the topic of several research analyst reports. The Goldman Sachs Group decreased their target price on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Chardan Capital reiterated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday, March 20th. Morgan Stanley raised their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, March 14th. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research note on Tuesday, March 18th. Finally, HC Wainwright reduced their target price on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.63.
Get Our Latest Research Report on RGNX
About REGENXBIO
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
